There was no evidence for a significantly differential treatment effect of telmisartan in hypertensive and nonhypertensive patients for any endpoints , although the occurrence of the secondary three-fold endpoint was significantly lower in the telmisartan group ( 13.0 % ) compared with placebo ( 15.0 % , P < 0.05 ) only in hypertensive patients .